Clinical trials: suspended, in China
Hypoparathyroidism
Efficacy and Safety of XH02 for the Treatment of Hypoparathyroidism
This study aims to evaluate the safety and efficacy of a novel PTH replacement therapy drug in patients with hypoparathyroidism.
- Trial name
- XH02 (NCT07197450)
- Testing
- intravenous administration of PTH1-84 mRNA
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Peking Union Medical College Hospital
Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma
This prospective, multicenter, phase II randomized controlled trial compares the efficacy and safety of SBRT combined with systemic therapy versus systemic therapy alone in BCLC stage C hepatocellular carcinoma (HCC).
- Trial name
- NCT07274774
- Testing
- Systemic therapy, Radiotherapy
- Where
- China
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- Shandong Cancer Hospital and Institute
Osteosarcoma, Soft Tissue Sarcoma
Safety and Efficacy of DIT309 in Advanced Bone and Soft Tissue Sarcomas
This is a open-Label, dose-escalation study to evaluate the safety, tolerability and antitumor activity of DIT309 in subjects with advanced bone and soft tissue sarcomas.The study also plan to explore the Maximum Tolerated Dose…
- Trial name
- NCT07052383
- Testing
- DIT309 cell injection
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Tcelltech Inc.
Solid Tumors
Phase I Study of TX103 CAR-T Cells in Participants With Advanced Solid Tumors
This is a single-arm, open-label, Phase I study to evaluate the safety, tolerability, and antitumor activity of TX103 CAR-T cells in subjects with TX103-positive advanced solid tumors.
- Trial name
- NCT07231081
- Testing
- Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103
- Where
- 2 sites in China
- Volunteers
- 85 people
- Sponsor
- Tcelltech Inc.
Gastric Outlet Obstruction
AXIOS™ Gastroenterostomy for Gastric Outlet Obstruction IDE
To investigate the safety and technical success of EUS-guided gastroenterostomy (EUS-GE) using the AXIOSTM lumen-apposing Metal Stent for the management of symptoms associated with gastric outlet obstruction from malignant…
- Trial name
- NCT06174805
- Testing
- AXIOS(TM) Stent and Electrocautery Enhanced Delivery System
- Where
- 10 sites in United States, Belgium and 4 more
- Volunteers
- 67 people
- Sponsor
- Boston Scientific Corporation
Glioma
IL13Rα2 CAR-T for Patients With r/r Glioma
This is a dose exploration clinical trial to assess the safety and feasibility of the IL13Ra2-targeted CAR-T in glioma.
- Trial name
- ENHANCING (NCT06355908)
- Testing
- IL13Rα2 CAR-T
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Yang Zhang
Lymphoma, B Cell Lymphoma
CD30 CAR-T in the Treatment of CD30 Positive Lymphoma
The is a prospective, open-label, dose-climbing multicenter clinical study assessing the efficacy and safety of CD30 CAR-T in the treatment of r/r CD30+ lymphoma. Plan to recruit 15 subjects with r/r CD30+ lymphoma。
- Conditions
- Lymphoma, B Cell Lymphoma, CD30+ Peripheral T-cell Lymphoma
- Trial name
- CAR-T，MTD (NCT07048353)
- Testing
- chimeric antigen receptor gene modified T cells
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Shandong Qilu Cell Therapy Engineering Technology Co., Ltd
Hypoparathyroidism
A Cohort Study on the Safety and Efficacy of XH-02 in Treating Hypoparathyroidism
XH-02 is an mRNA nucleic acid drug that expresses PTH in the body following intravenous or subcutaneous injection, providing PTH replacement therapy for patients with hypoparathyroidism.
- Trial name
- NCT07540286
- Testing
- Single subcutaneous injection, Multiple subcutaneous injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking Union Medical College Hospital
Hypoparathyroidism
Efficacy and Safety of Subcutaneous Injection of XH-02 in the Treatment of Adult Hypoparathyroidism
XH-02 is an mRNA nucleic acid drug that expresses PTH in the body following intravenous or subcutaneous injection, providing PTH replacement therapy for patients with hypoparathyroidism.
- Trial name
- NCT07530705
- Testing
- Single subcutaneous injection, Multiple subcutaneous injection
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Peking Union Medical College Hospital
Renal Cell Carcinoma (RCC), Lung Cancer
CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors
This study is a single-arm, open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CD70-targeted CAR-T cell preparations, and to preliminarily observe the study drug in…
- Conditions
- Renal Cell Carcinoma (RCC), Lung Cancer, Anaplastic Thyroid Carcinomas, Ovarian Cancer
- Trial name
- NCT07181720
- Testing
- CD70-targeted CAR-T cells
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Systemic Sclerosis (SSc)
Clinical Study of CD19 CAR-T in the Treatment of Refractory Systemic Sclerosis
This is an investigator-initiated trial aimed at assessing the safety and efficacy of anti-CD19 CAR-T cells in the treatment of childhood-onset systemic sclerosis
- Trial name
- NCT06792344
- Testing
- anti-CD19 CAR-T cells
- Where
- 2 sites in China, Christmas Island
- Volunteers
- 12 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Chronic Obstructive Pulmonary Disease
A Clinical Trial Comparing TQC3927 Inhaled Powder With Glycopyrronium Bromide and Formoterol Inhaled Aerosol (Biovoping® Lingchang®) for the Treatment of Chronic Obstructive Pulmonary Disease
This is a multicenter, randomized, open-label, positive-drug controlled study designed to evaluate the preliminary efficacy and safety of different doses of TQC3927 inhaled powder for short-term treatment of patients with chronic…
- Trial name
- NCT07633314
- Testing
- TQC3927 inhalation aerosol, Glyceryl bromide/formoterol inhalation aerosol
- Where
- 16 sites in China
- Volunteers
- 90 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Solid Tumor, Advanced Lymphoma
A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas
This is a first-in-human (FIH) study to evaluate the safety and preliminary efficacy of experimental drug CS5001 used as a single agent and in combination with systemic therapies in patients with advanced hematological and solid…
- Trial name
- NCT05279300
- Testing
- CS5001, Rituximab, Gemcitabine
- Where
- 38 sites in United States, Australia and 1 more
- Volunteers
- 480 people
- Sponsor
- CStone Pharmaceuticals
Gastrointestinal Stromal Tumors
A Prospective Study on Predicting Recurrence Risk of Postoperative High-risk GISTs in NED State Based on MRD Detection Via Liquid Biopsy
The goal of this single-center, prospective, observational cohort study is to learn whether tumor-informed minimal residual disease (MRD) testing in blood can predict recurrence in 66 patients with high-risk gastrointestinal…
- Trial name
- NCT05867901
- Testing
- Tumor-Informed ctDNA-Based MRD Testing, Contrast-Enhanced CT
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Peking University People's Hospital
Primary Open Angle Glaucoma
CRISPR/Cas9 Instantaneous Gene Editing Therapy to Intraocular Hypertensive POAG With MYOC Mutation
This study is intented to evaluate the safety, tolerability and preliminary efficacy of CRISPR/Cas9 Instantaneous Gene Editing Therapy (BD113 virus-like particle, also BD113vLVP) in patients with primary open-angle glaucoma…
- Trial name
- NCT06465537
- Testing
- BD113vVLP
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai BDgene Co., Ltd.
Locally Advanced Rectal Cancer
Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced Rectal Cancer (Neo-Field I)
The purpose of this study is to explore the efficacy and safety of involved-field radiotherapy-TNT combined with PD-1 inhibitors in pMMR locally advanced rectal cancer.
- Trial name
- NCT07057089
- Testing
- Capecitabine, Camrelizumab, CAPOX
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Hebei Medical University Fourth Hospital
Prostate Cancer
Application of a Novel Model Based on Plasma cfDNA Assay and MRl Imaging in the Detection of Prostate Cancer
The goal of this diagnostic test is to obtain multiple cell-free DNA （cfDNA） fragment profiles of subjects by whole genome sequencing based on plasma cfDNA, build a prostate cancer prediction model by machine learning, and to…
- Trial name
- NCT06509919
- Testing
- Blood draw and MRI scans
- Where
- 10 sites in China
- Volunteers
- 1,600 people
- Sponsor
- Shanghai Changzheng Hospital
Renal Cell Carcinoma
Anti-CD70-CAR-T Cell Injection for the Treatment of Locally Advanced or Relapsed/Metastatic CD70+ Inoperable Renal Cells
This is an investigator-initiated trial to evaluate the role of anti-CD70-CAR T cells in locally advanced or recurrent/metastatic renal cell carcinoma that is inoperable.
- Trial name
- NCT06586658
- Testing
- anti-CD70-CAR-T cells
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai Changzheng Hospital
Multiple Myeloma
A Clinical Study to Evaluate the Safety and Efficacy of ESO-T01 in Treating Relapsed/Refractory Multiple Myeloma.
This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability, preliminary efficacy and immunogenicity of ESO-T01 for patients with relapsed/refractory multiple myeloma.
- Trial name
- NCT06691685
- Testing
- ESO-T01 Injection
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma
A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma
Many osteosarcomas are cured with a variety of combined chemotherapy and surgery, but a significant number will still relapse.VEGF promotes an immunosuppressive microenvironment and contributes to immune checkpoint inhibitor…
- Trial name
- NCT05941325
- Testing
- fruquintinib, Envafolimab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai 6th People's Hospital